Russell Investments Group Ltd. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Russell Investments Group Ltd. increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 341,048 shares of the pharmaceutical company’s stock after acquiring an additional 27,326 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.13% of Vertex Pharmaceuticals worth $133,684,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in VRTX. Brighton Jones LLC raised its stake in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares during the last quarter. AE Wealth Management LLC boosted its stake in Vertex Pharmaceuticals by 112.0% during the 2nd quarter. AE Wealth Management LLC now owns 2,468 shares of the pharmaceutical company’s stock worth $1,099,000 after purchasing an additional 1,304 shares during the last quarter. Prospera Financial Services Inc grew its holdings in shares of Vertex Pharmaceuticals by 237.7% during the second quarter. Prospera Financial Services Inc now owns 10,235 shares of the pharmaceutical company’s stock worth $4,557,000 after buying an additional 7,204 shares in the last quarter. Sound View Wealth Advisors Group LLC grew its holdings in shares of Vertex Pharmaceuticals by 2.7% during the second quarter. Sound View Wealth Advisors Group LLC now owns 3,624 shares of the pharmaceutical company’s stock worth $1,613,000 after buying an additional 94 shares in the last quarter. Finally, Midwest Trust Co acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $254,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling

In other news, EVP Duncan Mckechnie sold 4,910 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total value of $2,394,361.50. Following the transaction, the executive vice president owned 17,559 shares of the company’s stock, valued at $8,562,646.35. This represents a 21.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Amit Sachdev sold 1,846 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $897,802.10. Following the transaction, the executive vice president owned 55,570 shares of the company’s stock, valued at approximately $27,026,469.50. This represents a 3.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 91,156 shares of company stock valued at $42,845,497. 0.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on VRTX shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $590.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Oppenheimer upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 price objective for the company in a report on Friday, February 13th. Canaccord Genuity Group raised their target price on shares of Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a research note on Tuesday, February 17th. Leerink Partners boosted their target price on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a report on Monday, December 29th. Finally, Wolfe Research upgraded Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price target for the company in a research report on Tuesday, January 6th. Twenty-two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $542.00.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER interim results: The company said a pre‑specified Week‑36 interim analysis of the Phase 3 RAINIER trial of povetacicept met the primary objective and all secondary endpoints, citing meaningful efficacy vs. placebo in adults with IgA nephropathy — the core catalyst driving the move. Business Wire release
• Positive Sentiment: Analyst reinforcement: William Blair’s Myles Minter reiterated a Buy and said confidence in povetacicept’s profile has increased after the RAINIER readout, strengthening the bullish investment case for VRTX. Analyst backing amplifies the positive reaction. TipRanks/William Blair note
• Positive Sentiment: Perception of high commercial potential: Coverage notes that povetacicept — acquired in a multibillion‑dollar deal — could be a best‑in‑class therapy in a competitive kidney disease market, supporting a longer‑term revenue upside if full data and approvals follow. BioPharmaDive article
• Neutral Sentiment: Market reaction and headlines: Media and trading outlets reported a sharp after‑hours/share surge following the announcement; that immediate momentum reflects sentiment but may be volatile as investors digest details and next steps. Benzinga coverage
• Negative Sentiment: Ongoing uncertainty: These are interim results from an ongoing trial — final RAINIER readout, safety follow‑up, regulatory timelines and payer/commercial execution remain unknown. Investors should weigh upside against the risk that final data or regulatory review could change the outlook. Yahoo Finance release

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $460.87 on Tuesday. The company has a 50 day simple moving average of $467.50 and a 200-day simple moving average of $435.79. The company has a market capitalization of $117.07 billion, a P/E ratio of 30.06 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.98 earnings per share. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.